Cobenfy (Xanomeline and Trospium Chloride)

Cobenfy is an oral fixed-dose combination (FDC) of xanomeline (a muscarinic agonist) and trospium chloride (a muscarinic antagonist). This therapeutic drug is used for the treatment of adult patients with schizophrenia.

Recommended Dosage: The recommended starting dosage of Cobenfy is one 50 mg/20 mg capsule (contains xanomeline 50 mg and trospium chloride 20 mg) orally twice daily for at least 2 days. The dosage can be increased to one 100 mg/20 mg capsule (contains xanomeline 100 mg and trospium chloride 20 mg) orally twice daily for at least 5 days. The dosage may be increased to one 125 mg/30 mg capsule (contains xanomeline 125 mg and trospium chloride 30 mg) orally twice daily based on patient tolerability and response. The maximum recommended dosage is 125 mg/30 mg orally twice daily. This therapeutic drug is taken orally at least 1 hour before a meal or at least 2 hours after a meal.

• Treatment with Xanomeline/Trospium Chloride may cause urinary retention, basically in patients with bladder outflow obstruction or preexisting conditions. Monitor for difficulty urinating, and adjust or stop treatment in case symptoms persist or worsen during administration.
• Patients struggling with hepatic impairment should use this medicine cautiously, as it may lead to drug accumulation and toxicity. Adjust dosing accordingly and monitor liver function clearly to prevent side effects associated with impaired metabolism.
• Treatment with Cobenfy 50 mg/20 mg, 100 mg/20 mg, and 125 mg/30 mg capsules may make biliary disease symptoms worse by exceeding cholinergic effects. Those with gallbladder disease or bile duct obstruction should use this medicine cautiously. healthcare providers (HCPs) should monitor patients for worsening symptoms.
• This therapeutic drug may reduce gastrointestinal motility, increasing the chance of constipation or gastric retention, basically in those with conditions like gastroparesis. Discontinue treatment in case of significant gastrointestinal discomfort or blockage.
• Angioedema, including painless swelling of the face, tongue, or throat, may occur in those taking this medicine. Stop using it immediately in case symptoms arise and seek emergency medical help to avoid critical complications.
• Xanomeline and Trospium Chloride may make symptoms of narrow-angle glaucoma worse by increasing intraocular pressure. Do not use the medicine in such patients. Regular eye exams are recommended for the timely detection of potential complications.
• Xanomeline/Trospium Chloride 50 mg/20 mg, 100 mg/20 mg, and 125 mg/30 mg capsules can cause tachycardia or palpitations. Those with cardiovascular complications, such as arrhythmias or uncontrolled hypertension, should be evaluated closely for exacerbation of symptoms
• This medicinal product may cause dizziness, drowsiness, or confusion, which may affect mental alertness. Patients should avoid activities that require focus, such as driving or operating machinery, until they understand the medicine’s effects.
• Treatment with this medicine should be avoided if you are pregnant unless the potential benefit outweighs the risk. Nursing mothers should avoid breastfeeding due to potential harm to the infant, as safety data are limited.

What documents are required to import COBENFY to India?

COBENFY (xanomeline and trospium chloride) capsules can be imported by patients or government hospitals on the name of the patients only.

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is COBENFY available in India?

COBENFY (xanomeline and trospium chloride capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Cobenfy in India (Mumbai, Kolkata,
• Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait,
• Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada,
• Europe, and Australia
• Ensuring 100% transparency.

COBENFY can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of COBENFY (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Cobenfy Capsule price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source the COBENFY (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Cobenfy®?

Xanomeline and Trospium Chloride is a Generic Name for the trade name drug Cobenfy®.

What is the Manufacturer's Name of Cobenfy®?

Cobenfy® is manufactured by Bristol-Myers Squibb Company.

Is Cobenfy® approved by the FDA?

Yes, Cobenfy® is approved by the FDA. Date of first approval: September 26, 2024.

What is the dosage and form of Cobenfy® supplied?

Cobenfy® is supplied in Capsules (xanomeline/trospium chloride): 50 mg/20 mg, 100 mg/20 mg, 125 mg/30 mg for oral use.

What are the most common side effects of Cobenfy®?

The most common side effects of Cobenfy® are nausea, vomiting, dyspepsia, constipation, hypertension, dizziness, abdominal pain, tachycardia, diarrhea, and gastrointestinal reflux disease.

How much does Cobenfy® (Xanomeline and Trospium Chloride) Capsules cost in India?

Prices of Cobenfy may vary over time because of market dynamics and regulatory changes. To get the accurate information on Cobenfy 50 mg/20 mg, 100 mg/20 mg, 125 mg/30 mg cost in India, kindly Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Cobenfy® be available in SAARC countries?

Apart from Gulf countries, Cobenfy® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the supply of Cobenfy® Capsuless in these countries, ensuring access to this therapeutic drug through legal and reliable channels.

Is it safe to buy Cobenfy® Capsules online in India?

Yes, one can buy Cobenfy online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Cobenfy® capsules through legal channels.

What are the storage conditions of Cobenfy® Capsules?

Store this medicinal product at 20-25°C (68°F to 77°F), with permitted excursions between 15-30°C (59°F to 86°F). Keep the capsules in a cool, dry place, away from heat and moisture.